Centenarian-associated SIRT6 hepatocellular carcinoma research program
preclinicalresearch program · medium · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Investigate whether centenarian-associated SIRT6 N308K/A313S variants suppress hepatocellular carcinoma aggressiveness and progression-related behavior.
AAV2/8-mediated overexpression of human centenarian-associated SIRT6 N308K/A313S in HCC cell lines with functional, transcriptomic, invasion, stiffness, and extracellular matrix analyses.
2026 Cancers publication reported preclinical HCC cell-line findings.
AAV2/8-mediated SIRT6 N308K/A313S overexpression hampered HCC cell proliferation, decreased invasion, increased intracellular stiffness, and modulated collagen/extracellular-matrix turnover genes, with stronger effects than wild-type SIRT6 in some assays.
SLAB Trial in Aged Beagles
preclinicalresearch program · high · Mon Oct 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate SIRT6-based longevity intervention in aged dogs, using dogs as a translational model for aging and as an entry point into pet longevity.
Sarcopenia and Longevity in Aged Beagles study using Genflow's SIRT6 gene therapy platform.
Aged-dog SLAB study listed in the company pipeline.
SLAB trial: Sarcopenia and Longevity in Aged Beagles
preclinicalresearch program · high · Mon Oct 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate SIRT6-based longevity intervention in aged dogs as a translational model for aging and as an entry into the pet longevity market.
Aged-dog study in beagles focused on sarcopenia and longevity outcomes.
Company materials list the SLAB trial as an active pipeline program; a 2025 CEO interview discussed using aging dogs as both a scientific model and pet longevity market strategy.
Exofastrack SIRT6 exosome therapy program
exploratoryplatform · high · Wed Jun 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Create an exosome-based therapeutic product targeting liver fibrosis in MASH and Werner Syndrome using SIRT6 payload delivery.
Three-year Genflow and EXO Biologics program to develop exosomes encapsulating an AAV or mRNA encoding SIRT6, including a photo-operation loading technique.
Received a €395,847 non-dilutive Wallonia ATMP grant representing 50% of the Exofastrack research grant, announced/discussed on 2024-06-12.
Exofastrack SIRT6 Exosome Therapy Program
exploratoryplatform · high · Wed Jun 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop exosome-based delivery of SIRT6 therapies for liver fibrosis in MASH and Werner Syndrome, an accelerated aging disease.
Therapeutic product composed of exosomes encapsulating an AAV or mRNA encoding SIRT6, using a photo operation technique for loading exosomes.
Received a €395,847 Wallonia ATMP grant supporting a three-year Genflow and EXO Biologics scientific program.
Centenarian-associated SIRT6 adipocyte function research program
preclinicalresearch program · medium · Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Clarify how centenarian-associated SIRT6 N308K/A313S affects adipogenesis, insulin sensitivity, and obesity-associated metabolic biology.
Lentiviral overexpression of SIRT6 wild-type or N308K/A313S in 3T3-L1 preadipocyte/adipocyte models, with histone post-translational modification profiling, RNA-seq, and biochemical pathway analysis.
2024 Clinical Epigenetics publication reported preclinical adipocyte model findings.
SIRT6 N308K/A313S overexpression increased adipogenic differentiation similarly to wild type, produced distinct histone and transcriptional profiles, and increased insulin sensitivity in an NPY-dependent manner.
GF-1002 SIRT6 gene therapy for advanced MASH
preclinicaldrug program · high · Sun Jan 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop a human therapy for advanced MASH by delivering a centenarian-associated SIRT6 gene variant to address age-related liver disease and fibrosis biology.
Adeno-associated viral vector delivery of a centenarian variant of SIRT6, with preparation for a Phase I/II clinical trial in advanced MASH.
Preparation for a Phase I/II clinical trial in advanced MASH is listed in the company pipeline material.
Preclinical publication evidence reports that centenarian-associated SIRT6 variants altered hepatocyte metabolomic/secretomic profiles and inhibited collagen deposition and fibrotic gene expression in hepatic 3D spheroids.
Centenarian SIRT6 Program for Adipocyte Function and Obesity Comorbidity Biology
preclinicalresearch program · medium
Clarify how centenarian-associated SIRT6 N308K/A313S variants affect adipogenesis, glucose sensitivity, and obesity-associated comorbidities.
Lentiviral overexpression of SIRT6 wild-type or N308K/A313S mutant in 3T3-L1 preadipocyte/adipocyte models with histone PTM, RNA-seq, biochemical, and bioinformatics analyses.
2024 Clinical Epigenetics publication reporting adipocyte model results.
SIRT6 N308K/A313S overexpression increased adipogenic differentiation similarly to wild type, produced distinct histone PTM and transcriptional profiles, and increased insulin sensitivity in an NPY-dependent manner.
Centenarian SIRT6 Program for Hepatocellular Carcinoma Biology
preclinicalresearch program · medium
Study whether centenarian-associated SIRT6 N308K/A313S variants can suppress hepatocellular carcinoma cell aggressiveness and behavior.
AAV2/8-mediated overexpression of human centenarian-associated SIRT6 N308K/A313S in HCC cell lines, with functional and transcriptomic analyses.
2026 Cancers publication reporting HCC cell-line results.
AAV2/8-mediated SIRT6 N308K/A313S overexpression hampered HCC cell proliferation, decreased invasion, increased stiffness, and modulated genes involved in collagen and extracellular matrix turnover.
GF-1002 SIRT6 Gene Therapy for Advanced MASH
preclinicaldrug program · high
Develop a human SIRT6-based gene therapy for advanced MASH and liver fibrosis by delivering a centenarian variant of SIRT6.
Adeno-associated viral vector delivery of centenarian-associated SIRT6; preparation for a Phase I/II clinical trial in advanced MASH.
Preparation for a Phase I/II clinical trial in advanced MASH.
Preclinical hepatic spheroid work reported that SIRT6 N308K/A313S overexpression altered hepatocyte metabolomic and secretomic profiles and inhibited collagen deposition and fibrotic gene expression.
